YGYingying Gao

Yingying Gao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yingying Gao has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Xiaoxiang Chen

    Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    2 shared publications
  • Haojie Chen

    Department of Rheumatology and Immunology, Nantong First People’s Hospital, Southeast University

    1 shared publication
  • Hongjun He

    Department of Rheumatology and Immunology, Taixing People’s Hospital, 98 Runtai South Road, Taixing 225400, China

    1 shared publication
  • Hua Wei

    Department of Rheumatology and Immunology, Northern Jiangsu People’s Hospital Affiliated to Yangzhou University

    1 shared publication
  • Huaixia Hu

    Department of Rheumatology and Immunology, Second People’s Hospital of Lianyungang, Lianyungang 222006, China

    1 shared publication
  • Jiale Zhang

    Department of Rheumatology and Immunology, Affiliated Nantong Clinical College of Nantong University, Nantong First People’s Hospital, Nantong 226001, China

    1 shared publication

Latest Publications

  • Open Access

    Severe thrombocytopenia is associated with arterial thrombotic manifestations in antiphospholipid syndrome: a two-center cohort study

    by Jie Kong, Yijing Su, Xinyun Zhu, Jingjing Zhao, Haojie Chen, Xiaoxiang Chen, Yingying Gao

    Objective: Thrombocytopenia in APS is often regarded primarily as a bleeding-related manifestation, but the relationship between platelet-count severity and thrombotic manifestations remains uncertain. We evaluated the association between severe thrombocytopenia and arterial thrombotic manifestations in patients with antiphospholipid syndrome (APS). Methods: In a two-center baseline cohort of 313 patients with APS, baseline platelet count (PLT) was categorized as PLT 9 /L, PLT 50–9 /L, or PLT ≥100×10 9 /L. Associations with prevalent baseline thrombotic manifestations were assessed using multivariable logistic regression in 300 patients with primary APS or systemic lupus erythematosus-associated APS. In the Renji follow-up cohort (n=254), 48-month thrombotic events were evaluated using Kaplan–Meier curves and Cox models. Results: PLT 9 /L was associated with a higher frequency of arterial thrombosis (66.7%), particularly cerebral infarction (62.7%), whereas venous thrombosis was most frequent in the PLT 50–9 /L group (68.4%). After multivariable adjustment, PLT 9 /L remained associated with a higher prevalence of arterial thrombosis (aOR 2.16, 95% CI 1.07–4.35, P = 0.032) and cerebral infarction (aOR 2.37, 95% CI 1.18–4.73, P = 0.015). During 48-month follow-up, PLT 9 /L was associated with increased risks of any thrombotic event (HR 3.28, 95% CI 1.54–6.97, P = 0.002), arterial thrombotic event (HR 3.95, 95% CI 1.39–11.21, P = 0.010), and cerebral infarction (HR 4.11, 95% CI 1.44–11.73, P = 0.008), but not venous-related events. Conclusion: Severe thrombocytopenia was associated with arterial thrombotic manifestations in APS, particularly cerebral infarction. PLT 9 /L may provide additional clinical risk information but may also reflect cumulative disease burden and overall APS severity.

  • Open Access

    Association Between Systemic Inflammatory Response Biomarkers and Disease Activity in Systemic Lupus Erythematosus: A Multi-Center Retrospective Study

    by Tao Ma, Jiale Zhang, Jie Kong, Hua Wei, Huaixia Hu, Yinshan Zang, Hongjun He, Wenwen Wang, Xiaoxiang Chen, Yingying Gao

    Objective: To evaluate the association of routine complete blood count (CBC)-derived inflammatory biomarkers, including neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR), and systemic inflammation response index (SIRI), with disease activity and exploratory neuropsychiatric risk stratification in patients with systemic lupus erythematosus (SLE). Methods: In this multi-center retrospective study, 579 SLE patients and 282 healthy controls (HCs) were recruited from five clinical centers between 2018 and 2025. NLR, MLR, PLR, and SIRI were calculated from routine CBC parameters. Disease activity was assessed using the SLE Disease Activity Index 2000 (SLEDAI-2K), with high activity defined as SLEDAI-2K ≥ 10. The comparison between SLE patients and HCs was performed as an exploratory descriptive analysis to characterize systemic inflammatory profiles, whereas the primary analyses focused on associations with disease activity and NPSLE-related risk stratification. Results: SLE patients exhibited significantly higher levels of SIRI, NLR, PLR, and MLR compared to HCs (all p < 0.001). In this exploratory comparison, MLR showed the largest area under the curve for distinguishing SLE patients from HCs (AUC: 0.849, Cut-off: 0.263). In regression analyses, MLR, NLR, PLR, and SIRI were positively associated with SLEDAI-2K score. In multivariable linear regression analysis, MLR was associated with a higher SLEDAI-2K score (B = 4.600, 95% CI: 2.039–7.160, p < 0.001). In patients with available neuropsychiatric data, MLR, NLR, and SIRI were higher in patients with NPSLE than in those with non-NPSLE, whereas PLR showed no significant difference. SIRI showed modest exploratory discriminatory ability for NPSLE and may provide auxiliary information for NPSLE risk stratification (AUC: 0.710, p < 0.001, Cut-off: 1.438). Conclusions: Routine CBC-derived inflammatory biomarkers, particularly MLR, NLR, and SIRI, are associated with SLE disease activity and may serve as accessible, low-cost adjunctive tools for rapid clinical assessment. SIRI may provide additional auxiliary information for identifying patients at higher risk of neuropsychiatric involvement. However, these biomarkers should be interpreted as complementary screening or risk-stratification tools rather than substitutes for established disease activity indices or organ-specific evaluations. Further prospective studies are warranted to validate their clinical utility.